Dr. Hammers is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
5323 Harry Hines Blvd
Dallas, TX 75390Phone+1 214-645-4673Fax+1 214-645-0078
Education & Training
Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2005 - 2009- Johns Hopkins University/Bayview Medical CenterResidency, Internal Medicine, 2002 - 2005
Certifications & Licensure
TX State Medical License 2016 - 2026
MD State Medical License 2009 - 2022
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013-2014
Clinical Trials
- Randomized Salvage Radiation Therapy Plus Enzalutamide Post Prostatectomy Start of enrollment: 2015 Mar 28
- SBRT (Stereotactic Body Radiation Therapy) in Combination With Nivolumab/Ipilimumab in Renal Cell Carcinoma (RCC) / Kidney Cancer Patients Start of enrollment: 2017 Mar 01
Publications & Presentations
PubMed
- 3 citationsTivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 S...Toni K Choueiri, Laurence Albiges, Philippe Barthélémy, Roberto Iacovelli, Sheik Emambux
Lancet. 2024-10-05 - 1 citationsPathological Response and Outcomes in Patients With Metastatic Renal Cell Carcinoma (mRCC) Receiving Immunotherapy-Based Therapies and Undergoing Deferred Cytoreductiv...Damla Gunenc, Wadih Issa, Thomas Gerald, Qinhan Zhou, Song Zhang
Clinical Genitourinary Cancer. 2024-10-01 - Treatment-free survival and partitioned survival analysis of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib: 5-yea...Charlene M Mantia, Opeyemi A Jegede, Elizabeth R Plimack, Thomas Powles, Robert J Motzer
Journal for Immunotherapy of Cancer. 2024-07-25
Press Mentions
Adding Targeted Agent to Perioperative Therapy for RCC May Improve Disease ControlNovember 11th, 2024- National Cancer Institute Renews $11.5 Million Program of Excellence Award in Kidney CancerSeptember 19th, 2022
UT Southwestern Develops Test to Predict Immunotherapy Response in Kidney CancerJune 4th, 2019- Join now to see all
Professional Memberships
- Member
- Member
Other Languages
- German
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
